Bibliographic Details
| Title: |
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| Authors: |
Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard |
| Source: |
Cancer Medicine, Vol 9, Iss 8, Pp 2643-2652 (2020) |
| Publisher Information: |
Wiley, 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Immune checkpoint inhibitor, pseudoprogression, response evaluation criteria in solid tumors, treatment beyond progression, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti‐PD(L)‐1. Methods All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti‐PD(L)‐1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results A total of 169 patients treated with anti‐PD(L)‐1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non‐small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT‐scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune‐related response evaluations may require further attention. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2045-7634 |
| Relation: |
https://doaj.org/toc/2045-7634 |
| DOI: |
10.1002/cam4.2797 |
| Access URL: |
https://doaj.org/article/a4e7a1041c934bc3942c24fc39614624 |
| Accession Number: |
edsdoj.4e7a1041c934bc3942c24fc39614624 |
| Database: |
Directory of Open Access Journals |
